retatrutide phase 2 trial type 2 diabetes weight loss 2024 Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in and A1C Retatrutide Before and After: Doctor

As the ABC noted in its reporting on the Victorian cases, the injectable medication has not been approved by any worldwide drug regulator. It is still moving through clinical trials, where it is one of the most effective compounds the obesity field has ever produced

2026 Jun 11 [cited 2026 Jun 15]

FTO regulates the amount of fat deposition and affects T2D risk through its effect on BMI

Semaglutide 2.4 mg (Wegovy) is approved under NICE technology appraisal TA875, and tirzepatide (Mounjaro) has also received a NICE technology appraisal for weight management

Dao K, Shechtman S, Weber-Schoendorfer C, Diav-Citrin O, Murad RH, Berlin M, et al